A new network launched by Facebook CEO Mark Zuckerberg and his wife, Priscilla Chan, will unite leading investigators from various biomedical fields, as well as biologists and physicians, in gaining insight into why neurodegenerative disorders such as Parkinson’s occur. The Chan Zuckerberg Initiative’s (CZI) Neurodegeneration Challenge Network will focus…
News
A concoction made from several Chinese herbal medicines helped reduce brain inflammation and promoted nerve cell survival in a mouse model of Parkinson’s disease, a study finds. The study, “Curative Anti-Inflammatory Properties of Chinese Optimized Yinxieling Formula in Models of Parkinson’s Disease,” was published in Evidence-Based Complementary and Alternative Medicine.
Neurodegeneration in the substantia nigra, a critical area of the brain involved in Parkinson’s, leads to memory deficits, according to a study that explored the effects of levodopa on a rat model of the disease. Findings of the study, titled “Implication of nigral dopaminergic lesion and repeated L-dopa exposure in…
Small Vessel Disease Linked to Severity of Motor Impairment in Parkinson’s Patients, Study Finds
A disorder related to tiny blood vessels in the brain, known as cortical small vessel disease, is directly linked to worsening motor function in Parkinson’s disease, according to a recent study. An additional association between modifiable vascular risk factors, in particular hypertension, and dementia highlights the need to…
Defective Activity of GCase Enzyme Linked with Neurodegeneration in Parkinson’s, Mouse Study Finds
Impaired activity of the enzyme glucocerebrosidase (GCase), which is responsible for breaking down and recycling cell waste, boosts neurodegeneration and accumulation of alpha-synuclein in Parkinson’s, according to a new mouse study. The research, “Development and biochemical characterization of a mouse model of Parkinson’s disease bearing defective…
Voyager Therapeutics has begun patient dosing in a Phase 2 trial testing its investigational VY-AADC gene therapy in Parkinson’s patients whose motor symptoms are not responding adequately to oral medication. The trial, called RESTORE-1 (NCT03562494), is recruiting participants across seven sites in the United States. VY-AADC is a therapy that delivers…
IRL790, Integrative Research Laboratories‘ investigational treatment for Parkinson’s disease patients, was safe and reduced levodopa-induced dyskinesia, a Phase 1b trial shows. The results were published in the journal npj Parkinson’s Disease in the study, “Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced…
Older patients with inflammatory bowel disease (IBD) are more likely to develop Parkinson’s disease than those without the condition, a meta-analysis suggests. Whether the same association exists for younger patients — ages 59 or younger — remains to be determined, according to the researchers. The study, “Older…
Ingesting a once widely used herbicide called paraquat along with lectins — proteins in common foods that bind carbohydrates (e.g., sugars) — can lead to symptoms typical of Parkinson’s disease and known as parkinsonism, a study reported. Importantly, this animal research provides a new preclinical model for testing…
With the goal of establishing a consensus on medical marijuana use by Parkinson’s patients — which a recent survey co-sponsored by the Parkinson’s Foundation put at 80 percent — the group will host its first conference focused on this compound and the disease. Set for March 6-7 in Denver, the invitation-only meeting…
Recent Posts
- Merz honors resiliency of Parkinson’s community with new US campaign
- Lessons revealed in the quiet moments of Parkinson’s caregiving
- Gut immune cells may help Parkinson’s spread from the belly to the brain
- New delivery system guides curcumin to Parkinson’s-affected brain cells
- New $2M MJFF grant backs Parkinson’s walking study at Boston University